Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
New data presented at ASH 2021 highlight potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in earlier lines of multiple myeloma treatment
GSK announced new data from the DREAMM-9 phase I trial and two GSK collaborative studies investigating the potential use of Blenrep.
-
Medicago and GSK announce positive Phase 3 efficacy and safety results for adjuvanted plant-based COVID-19 vaccine candidate
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by COVID-19 variants
-
Preclinical studies demonstrate sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant
New preclinical findings generated through in vitro testing of sotrovimab against the complete pseudo-virus, updated to bioRxiv
-
GSK welcomes Gavi decision to fund the roll out of malaria vaccines for children
Gavi to provide funding for procurement and introduction of malaria vaccines into child immunisation programmes in Gavi eligible countries.
-
MHRA grants conditional marketing authorisation1 for COVID-19 treatment Xevudy (sotrovimab)
Conditional marketing authorisation has been granted for Great Britain and is based on Phase III data
-
GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease
The institute aims to deepen understanding of complex diseases such as Alzheimer’s and Parkinson’s, and increase drug discovery.
-
Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant
Data to be confirmed by further in vitro pseudo-virus testing
-
GSK unveils Target the Future, a global, multi-year programme to help address key challenges affecting the multiple myeloma community
$100,000 grant to be awarded to best idea submitted to Target the Future Think Tank Challenge
-
GSK appoints Phil Dormitzer M.D., Ph.D., as Global Head of Vaccines R&D
Phil Dormitzer M.D., Ph.D., will join the company as Global Head of Vaccines R&D on 3 December 2021
-
GSK showcases progress from the DREAMM clinical trial programme in multiple myeloma at the 2021 ASH Annual Meeting
11 abstracts on Blenrep will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition.
-
GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment
US government contracts for approximately $1 billion (USD) now in place to purchase sotrovimab, further expanding access nationwide
-
European Commission approves Nucala (mepolizumab) in three additional eosinophil-driven diseases
Mepolizumab is now the only treatment approved in Europe for use in four eosinophil-driven diseases
-
Primary endpoint met in COMET-TAIL Phase III trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
Phase III IM administration data for sotrovimab.
-
GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease
Pivotal trials in non-dialysis and dialysis populations published simultaneously in the New England Journal of Medicine
-
ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be implemented successfully in a variety of European healthcare settings
The CARISEL study showed most people living with HIV who started treatment felt positive about the long-acting regimen
-
GSK delivers strong Q3 sales of £9.1 billion +5% AER, +10% CER Total EPS 23.3p -7% AER, +3% CER; Adjusted EPS 36.6p +3% AER, +10% CER 2021 full year EPS guidance improved
Sales growth across Pharmaceuticals, Vaccines and Consumer Healthcare driven by strong commercial execution and underlying demand
-
GSK announces Dr Harry (Hal) C. Dietz MD to join the Board as Non-Executive Director
Appointment further strengthens Board scientific capabilities, including in genetics which is central to GSK’s R&D approach
-
GSK Consumer Healthcare solidifies commitment to pharmacists with 3-year Pharmacist Support Programme
Helping global pharmacy teams play a critical role in improving public health in the age of self-care.
-
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up
US CDC and Prevention’s Advisory Committee votes unanimously to recommend Shingrix for immunocompromised adults aged 19 & up
-
Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040
The report offers actions to overcome the barriers that have blocked progress in achieving health equity across HIV, STIs, & COVID-19
